Related Experiment Videos
Altering molecular mechanisms to prevent sudden arrhythmic death
1Texas Arrhythmia Institute, Houston 77030, USA.
Abstract:
Trials of drug treatment for prevention of sudden arrhythmic death have been disappointing, perhaps because suppressive therapy with arrhythmic agents fails to address the mechanisms leading to electrophysiological failure. We propose that preventive treatment should pay more attention to molecular mechanisms responsible for the progression of cardiac disease to electrophysiological failure. Most sudden cardiac deaths occur in people with atherogenic dyslipidaemias. Our hypothesis is that the pathogenic molecular mechanisms of dyslipidaemias contribute directly to arrhythmogenesis. Proinflammatory-prothrombotic lipid-derived mediators that may play a part in arrhythmogenesis include phospholipids and leucotrienes acting through the platelet-activating-factor and peroxisome proliferator-activated-receptor pathways. There are drugs available to test the hypothesis of dyslipidaemias-specific prevention of electrophysiological failure.
Insights
Preventing sudden arrhythmic death requires targeting molecular mechanisms of cardiac disease progression. Atherogenic dyslipidemias may directly cause arrhythmias through lipid mediators, suggesting new therapeutic targets.
Area of Science:
- Cardiology
- Molecular Medicine
- Pharmacology
Background:
- Sudden arrhythmic death prevention trials using antiarrhythmic drugs have yielded disappointing results.
- Current therapies may fail to address the underlying molecular mechanisms of electrophysiological failure in cardiac disease.
Purpose of the Study:
- To propose a shift in preventive strategies for sudden arrhythmic death, focusing on molecular mechanisms driving cardiac electrophysiological failure.
- To investigate the hypothesis that pathogenic molecular mechanisms of atherogenic dyslipidemias directly contribute to arrhythmogenesis.
Main Methods:
- Review of existing literature on sudden cardiac death, dyslipidemias, and molecular pathways involved in arrhythmogenesis.
- Identification of lipid-derived mediators (phospholipids, leucotrienes) and their associated signaling pathways (platelet-activating factor, peroxisome proliferator-activated receptor) implicated in arrhythmogenesis.
- Consideration of available drugs for testing the proposed hypothesis.
Main Results:
- Sudden cardiac deaths frequently occur in individuals with atherogenic dyslipidemias.
- Proinflammatory-prothrombotic lipid mediators, including phospholipids and leucotrienes, are implicated in arrhythmogenesis via specific molecular pathways.
- Existing pharmacological agents can be utilized to test the hypothesis linking dyslipidemias to electrophysiological failure.
Conclusions:
- Preventive strategies for sudden arrhythmic death should address the molecular underpinnings of cardiac disease progression and electrophysiological failure.
- Atherogenic dyslipidemias represent a potential direct contributor to arrhythmogenesis through specific lipid-mediated pathways.
- Targeting dyslipidemia-specific molecular mechanisms offers a promising avenue for the prevention of sudden arrhythmic death.